Overview
© 202 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Conference | American Society of NephrologyThe treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.Atrasentan results in meaningful reductions in a number of cardiovascular data points in patients with type 2 diabetes and chronic kidney disease (CKD).A team, led by Pragyi Shrestha, Universitair Medisch Centrum Groningen, asesed whether albuminuria and lipids with atrasentan reduction also reduces PCKS9 and/or syndecan-1 sheding.The endothelin receptor antagonist atrasentan is known to reduce albuminuria and coincide with reductions in LDLc and triglycerides.Previous research shows albuminuria can increase protein convertase subtilisin kexin type 9 (PCSK9), syndecan-1 sheding, and/or PCSK9-syndecan-1 interaction.
Key Information
This leads to the impairment of hepatic lipoprotein clearance.In the phase 2 study, the investigators examined patients with type 2 diabetes and chronic kidney disease. Each participant was randomized to receive either atrasentam 0.75 mg daily or 1.25 mg daily (n = 94) or placebo (n = 26) for 12 weks. Each patient was stabilized to a maximum labeled dose of RAS inhibitor.The data was presented during the 202 American Society of Nephrology (ASN) Anual Meting in Orlando.The investigators measured urine albumin creatine ratio (UACR), serum lipids.
PCSK9, and syndecan-1 at baseline and wek 12.The results show treatment reduced UACR by 37.1% (95% CI, 30.1-43.4; P <0.01). Atrasetan also resulted in reductions in LDLc by 17.12 mg/dL (95%CI, 8.8-25.4; P <0.01), triglycerides by 47.4 mg/dL (95% CI, 40.4-90.5; P <0.01), and PCSK9 by -25.9 ng/mL (95% CI, -52.7 to 1.0 (P = 0.061) compared to placebo.In adition, they did not observe any efects on HDLc and syndecan-1.
Summary
After conducting a multivariate analysis adjusted for baseline demographics, lipid, and kidney function parameters, the investigators found achieved albuminuria leve